112天零新增+63天零通过：赴美上市备案再度暂停，企业下一步怎么走？

Group 1 - The core point of the article highlights a significant stagnation in Chinese companies' filings for U.S. listings, with 112 days without new applications and 63 days without any approvals, indicating a cautious approach from companies and a slowdown in the regulatory process [2][3][7] - The current situation reflects a dual pressure from increased regulatory scrutiny in China and heightened listing requirements in the U.S., making it more challenging for Chinese companies to go public in the U.S. [7][8] - The upcoming Spring Festival provides a timely opportunity for companies to reassess their listing strategies, emphasizing that the essence of going public is to raise funds for development rather than merely achieving a listing status [8][12] Group 2 - Companies are encouraged to consider alternative paths for listing, such as the OTC market, which does not require the lengthy approval process and can facilitate access to international capital [9][11] - The OTC market offers advantages like reduced listing barriers and time costs, allowing companies to gain compliance experience and prepare for potential future listings on major U.S. exchanges [11][12] - Companies should focus on aligning their listing strategies with their specific circumstances and ensure compliance as a foundational aspect of long-term development [8][9]